Targeting SSTR2 Shows Promise for Aggressive SDHB-Deficient Neuroendocrine Tumors
Background
Pheochromocytomas and paragangliomas (PPGLs) are rare neuroendocrine tumors that originate from chromaffin cells. A subset of these tumors, particularly those with Succinate Dehydrogenase B (SDHB) deficiency, are often more aggressive and have limited treatment options. Current therapies primarily involve surgery, but for metastatic or recurrent cases, effective systemic treatments are scarce, highlighting a critical unmet medical need. Therefore, identifying specific molecular vulnerabilities in SDHB-deficient PPGLs is crucial for developing novel, targeted therapeutic strategies.
Results
The study revealed a significantly higher and more consistent expression of somatostatin receptor subtype 2 (SSTR2) in SDHB-deficient tumors compared to other SSTR subtypes or SDHB-proficient controls. Activation of SSTR2 with the somatostatin analog pasireotide (0.1-100 nM) led to a significant reduction in cell proliferation, demonstrating a 43% decrease (p<0.001) in SDHB-deficient cell lines after 72 hours. > The most important finding was that SSTR2 activation specifically inhibited tumor cell growth and viability in SDHB-deficient models, exhibiting a 2.8-fold greater anti-proliferative effect compared to SDHB-proficient control cells. Furthermore, SSTR2 activation induced apoptosis (programmed cell death) in SDHB-deficient cells, with a 35% increase in apoptotic markers like cleaved caspase-3, suggesting a direct cytotoxic effect. This indicates that SSTR2 acts as a critical and exploitable vulnerability in these aggressive tumors.
Why It Matters
This research identifies SSTR2 as a highly promising therapeutic target for aggressive SDHB-deficient pheochromocytomas and paragangliomas, offering a novel strategy for a disease with limited options. The fact that SSTR2 agonists, such as pasireotide and octreotide, are already clinically approved for other neuroendocrine tumors (e.g., acromegaly, neuroendocrine gastroenteropancreatic tumors) could significantly accelerate their repurposing for SDHB-deficient PPGLs. Future steps should include rigorous preclinical validation in in vivo animal models to confirm efficacy and safety, paving the way for Phase II clinical trials to evaluate SSTR2 agonists in patients with SDHB-deficient PPGLs.